Elan (ELN) and Biogen (BIIB) Weak On Jump In Tysabri PML Cases
Shares of Elan (NYSE: ELN) and partner Biogen Idec Inc. (Nasdaq: BIIB) are under pressure today after there was a meaningful jump in cases of a fatal brain disease, PML, related to the companies MS drug Tysabri. There are now 23 cases, versus 16 prior cases.
In a statement today, the European Medicines Agency said they will review "any additional measures necessary to ensure the safe use of Tysabri and how to balance the risks to the patients against the benefits of the treatment."
Analyst at R.W. Baird said the jump in cases is not surprising. The firm said, "at worst, we anticipate CHMP may recommend a drug holiday after an extended period on therapy, but is unlikely to suspend Tysabri's marketing authorization." The firm is maintaining their Neutral rating on share of Biogen Idec.
Shares of Biogen Idec are down 6 percent and shares of Elan are down 21 percent in early trading.
Real-Time Market Moving News - Two Weeks Free http://www.streetinsider.com/premium_content.php
Create E-mail AlertRelated Categories
FDAInsiders' Blog
Trader Talk
Stocks Mentioned
-1.82Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
